Natriuretic Peptide as an Adjunctive Diagnostic Test in the Acute Phase of Kawasaki Disease
- 482 Downloads
Coronary arteritis rather than myocardial involvement is typically emphasized in Kawasaki disease (KD). Moreover, the criteria and the usual biological markers oversee the importance of cardiac-specific markers in diagnosing this disease. We sought to study the clinical usefulness of measuring B-type natriuretic peptide (BNP) and its N-terminal moiety (NT-proBNP) at the onset of KD. Our objective was to evaluate blood concentrations of BNP and NT-proBNP during the acute and subacute phases of KD. We conducted a prospective study comparing newly diagnosed KD patients to non-KD febrile controls. Blood specimens were collected at presentation, 6–12 h after intravenous immunoglobulin (IVIG) therapy, 1–2 weeks later, and 2–3 months later, or only upon reenrollment for controls. Forty-there KD and 19 control patients were enrolled consecutively. The mean age was 47.1 ± 34.3 and 62.2 ± 44.9 months, respectively (p = NS). Pre-IVIG NT-proBNP levels were significantly higher in KD patients than in controls (923.6 ± 1361.7 vs. 186.2 ± 198.0 ng/L; p < 0.001), with no statistical difference for BNP (141.9 ± 227.5 vs. 59.9 ± 72.4 ng/L; p = 0.112). In conclusion, our data indicate that NT-proBNP is a better marker of myocardial involvement in acute KD than BNP, particularly in cases with incomplete diagnostic criteria, and suggest that it may be a valid adjunctive diagnostic method to support the diagnosis of KD.
KeywordsB-type natriuretic peptide (BNP) N-terminal moiety of BNP (NT-proBNP) Carditis Myocardial dysfunction
Costs of natriuretic peptide measurements were provided by Roche-Diagnostics Canada and Abbott Canada.
- 3.Ayusawa M, Kanamaru H, Karasawa K, Noto N, Sumitomo N, Yamaguchi H, Izumi H, Okada T, Harada K (2002) Estimation of “selective” intravenous gamma globulin treatment indicated by Harada score. Pediatr Res 53(1):181 (abstr)Google Scholar
- 6.Burns JC, Mason WH, Glode MP, Shulman ST, Melish ME, Meissner C, Bastian J, Beiser AS, Meyerson HM, Newburger JW (1991) Clinical and epidemiologic characteristics of patients referred for evaluation of possible Kawasaki disease. United States Multicenter Kawasaki Disease Study Group. J Pediatr 118(5):680–686PubMedCrossRefGoogle Scholar
- 8.Costello-Boerrigter LC, Boerrigter G, Redfield MM, Rodeheffer RJ, Urban LH, Mahoney DW, Jacobsen SJ, Heublein DM, Burnett JC (2006) Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 47:345–353PubMedCrossRefGoogle Scholar
- 15.Ishii M, Ueno T, Ikeda H, Iemura M, Sugimura T, Furui J, Sugahara Y, Muta H, Akagi T, Nomura Y, Homma T, Yokoi H, Nobuyoshi M, Matsuishi T, Kato H (2000) Sequential follow-up results of catheter intervention for coronary artery lesions after Kawasaki disease: quantitative coronary artery angiography and intravascular ultrasound imaging study. Circulation 105:3004–3010CrossRefGoogle Scholar
- 18.Kavey RE, Allada V, Daniels SR, Hayman LL, McCrindle BW, Newburger JW, Parekh RS, Steinburger J (2006) Cardiovascular risk reduction in high-risk pediatric patients. A scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research. Circulation 114:2710–2738PubMedCrossRefGoogle Scholar
- 21.Kawasaki T (1967) Acute febrile mucocutaneous syndrome. Jpn J Allergy 16:178–222Google Scholar
- 26.McCrindle BW, Li JS, Minich LL, Colan SD, Atz AM, Takahashi M, Vetter VL, Gersony WM, Mitchell PD, Newburger JW, for the Pediatric Heart Network Investigators (2007) Coronary artery involvement in children with Kawasaki disease risk factors from analysis of serial normalized measurements. Circulation 116:174–179PubMedCrossRefGoogle Scholar
- 35.Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA (2004) Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 110:2747–2771PubMedCrossRefGoogle Scholar
- 42.Tseng CF, FU YC, Fu LS, Betau H, Chi CS (2001) Clinical spectrum of Kawasaki disease in infants. Zhonghua Yi Xue Za Zhi (Taipei) 64:168–173Google Scholar
- 46.Wilson Tang WH (2007) B-type natriuretic peptide: a critical review. CHF 13:48–52Google Scholar
- 47.Yonesaka S, Takahashi T, Matubara T, Nakada T, Furukawa H, Tomimoto K, Oura H (1991) Histopathological study on Kawasaki disease with special reference to the relation between the myocardial sequellae and regional wall motion abnormalities of the left ventricle. Jpn Circ C 56:352–358Google Scholar